{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:34:46Z","timestamp":1792416886766,"version":"4.4.0"},"reference-count":151,"publisher":"Oxford University Press (OUP)","issue":"37","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,1]]},"DOI":"10.1093\/eurheartj\/ehy407","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T12:15:15Z","timestamp":1530101715000},"page":"3417-3438","source":"Crossref","is-referenced-by-count":47,"title":["Association is not causation: treatment effects cannot be estimated from observational data in heart failure"],"prefix":"10.1093","volume":"39","author":[{"given":"Christopher J","family":"Rush","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross T","family":"Campbell","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"key\n\t\t\t\t20181001045237_ehy407-B1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(00)03651-5","article-title":"Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials","volume":"357","author":"Collins","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/bmj.321.7256.255","article-title":"Which clinical studies provide the best evidence? The best RCT still trumps the best observational study","volume":"321","author":"Barton","year":"2000","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0002-9343(82)90815-4","article-title":"Randomized versus historical controls for clinical trials","volume":"72","author":"Sacks","year":"1982","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM197607082950204","article-title":"Randomized clinical trials. Perspectives on some recent ideas","volume":"295","author":"Byar","year":"1976","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B5","doi-asserted-by":"crossref","first-page":"e0145294.","DOI":"10.1371\/journal.pone.0145294","article-title":"Media coverage, journal press releases and editorials associated with randomized and observational studies in high-impact medical journals: a cohort study","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B6","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/cts.12178","article-title":"Big data and large sample size: a cautionary note on the potential for bias","volume":"7","author":"Kaplan","year":"2014","journal-title":"Clin Transl Sci"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B7","doi-asserted-by":"crossref","first-page":"f6409","DOI":"10.1136\/bmj.f6409","article-title":"Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research","volume":"347","author":"Freemantle","year":"2013","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B8","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/aje\/kwp137","article-title":"Invited Commentary: assessing treatment effects by using observational analyses\u2013opportunities and limitations","volume":"170","author":"Wang","year":"2009","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(02)07451-2","article-title":"Bias and causal associations in observational research","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.7326\/0003-4819-115-11-901","article-title":"Discussing hidden bias in observational studies","volume":"115","author":"Rosenbaum","year":"1991","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcin.2016.03.003","article-title":"Big trials or big data","volume":"9","author":"King","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B12","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1200\/JCO.2012.45.9792","article-title":"Comparative effectiveness research in oncology: an overview","volume":"30","author":"Lyman","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B13","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2217\/cer.12.49","article-title":"Observational studies versus randomized trials: squaring off","volume":"1","author":"Greenfield","year":"2012","journal-title":"J Comp Eff Res"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jclinepi.2017.04.022","article-title":"Adjusting for unmeasured confounding in nonrandomized longitudinal studies: a methodological review","volume":"87","author":"Streeter","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/sim.2739","article-title":"The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials","volume":"26","author":"Rubin","year":"2007","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jama.297.3.314","article-title":"Estimating treatment effects using observational data","volume":"297","author":"D\u2019Agostino","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B17","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.7326\/0003-4819-133-12-200012190-00008","article-title":"A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease","volume":"133","author":"Grodstein","year":"2000","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":". Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B20","doi-asserted-by":"crossref","first-page":"i3283","DOI":"10.1136\/bmj.i3283","article-title":"Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data","author":"Matthews","year":"2016","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B21","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B22","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B23","doi-asserted-by":"crossref","first-page":"b2535.","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B24","doi-asserted-by":"crossref","first-page":"d5928.","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000138934.28340.ED","article-title":"National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction","volume":"110","author":"Masoudi","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2016.05.008","article-title":"Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure","volume":"129","author":"Sanam","year":"2016","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.hlc.2014.02.022","article-title":"Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China. Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ)","volume":"23","author":"Liu","year":"2014","journal-title":"Hear Lung Circ"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B29","doi-asserted-by":"crossref","first-page":"2108.","DOI":"10.1001\/jama.2012.14785","article-title":"Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction","volume":"308","author":"Lund","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B30","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1253\/circj.CJ-15-0514","article-title":"Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan. Report from the CHART studies","volume":"79","author":"Ushigome","year":"2015","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijcard.2008.10.033","article-title":"Mortality and morbidity of non-systolic heart failure treated with angiotensin-converting enzyme inhibitors: a propensity-adjusted case-control study","volume":"139","author":"Gomez-Soto","year":"2010","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjcard.2007.08.050","article-title":"Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients \u226565 years of age with heart failure and preserved left ventricular systolic function","volume":"101","author":"Shah","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.amjcard.2007.10.026","article-title":"Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure","volume":"101","author":"Tribouilloy","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cardfail.2005.09.001","article-title":"Angiotensin-converting enzyme inhibitors prescription is associated with longer survival among patients hospitalized for congestive heart failure who have preserved systolic function: a long-term follow-up study","volume":"12","author":"Grigorian Shamagian","year":"2006","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.amjmed.2013.01.004","article-title":"Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction","volume":"126","author":"Mujib","year":"2013","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1054\/jcaf.2001.26896","article-title":"Congestive heart failure with preserved systolic function in a statewide sample of community hospitals","volume":"7","author":"Dauterman","year":"2001","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(00)00601-X","article-title":"Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors","volume":"109","author":"Philbin","year":"2000","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B38","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0002-8703(97)70123-6","article-title":"Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function","volume":"134","author":"Philbin","year":"1997","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B39","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/eurjhf\/hfs101","article-title":"Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study","volume":"14","author":"Patel","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ejheart.2007.03.004","article-title":"Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure","volume":"9","author":"Keyhan","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B41","doi-asserted-by":"crossref","first-page":"769.","DOI":"10.1001\/archinte.164.7.769","article-title":"The use of \u03b2-blockers in a tertiary care heart failure clinic","volume":"164","author":"Tandon","year":"2004","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B42","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/gerona\/59.7.M716","article-title":"Use of angiotensin-converting enzyme inhibitors in elderly people with heart failure: prevalence and outcomes","volume":"59","author":"Pedone","year":"2004","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/01.SMJ.0000051271.11872.50","article-title":"Heart failure mortality among older Medicare beneficiaries: association with left ventricular function evaluation and angiotensin-converting enzyme inhibitor use","volume":"96","author":"Ahmed","year":"2003","journal-title":"South Med J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B44","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0002-9343(02)01346-3","article-title":"The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure","volume":"113","author":"Sin","year":"2002","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.mayocp.2012.02.018","article-title":"Statins in heart failure: the paradox between large randomized clinical trials and real life","volume":"87","author":"Gastelurrutia","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5694\/j.1326-5377.2010.tb03528.x","article-title":"The effect of evidence-based medication use on long-term survival in patients hospitalised for heart failure in Western Australia","volume":"192","author":"Teng","year":"2010","journal-title":"Med J Aust"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jchf.2016.10.015","article-title":"Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: an AF-CHF substudy","volume":"5","author":"Cadrin-Tourigny","year":"2017","journal-title":"JACC Hear Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjmed.2014.11.036","article-title":"Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure","volume":"128","author":"Bhatia","year":"2015","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B49","first-page":"495","article-title":"Temporal variation in the prognosis and treatment of advanced heart failure\u2014before and after 2000","author":"Del Carlo","year":"2014","journal-title":"Arq Bras Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B50","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2014.15241","article-title":"Association between use of \u03b2-blockers and outcomes in patients with heart failure and preserved ejection fraction","volume":"312","author":"Lund","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cardfail.2012.11.011","article-title":"Comparison of \u03b2-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction","volume":"19","author":"El-Refai","year":"2013","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B52","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3892\/etm.2013.1341","article-title":"Prognosis of patients with heart failure and reduced ejection fraction in China","volume":"6","author":"Xu","year":"2013","journal-title":"Exp Ther Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jacc.2008.09.031","article-title":"Clinical effectiveness of beta-blockers in heart failure. Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry","volume":"53","author":"Hernandez","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1253\/circj.CJ-07-1016","article-title":"Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction","volume":"73","author":"Miyagishima","year":"2009","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B55","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.amjcard.2008.09.064","article-title":"Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure","volume":"103","author":"Fauchier","year":"2009","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B56","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.amjcard.2008.07.059","article-title":"Comparison of late mortality in hospitalized patients >70 years of age with systolic heart failure receiving beta blockers versus those not receiving beta blockers","volume":"102","author":"Pascual-Figal","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B57","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1093\/eurheartj\/ehi473","article-title":"Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study","volume":"26","author":"Jost","year":"2005","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B58","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1054\/jcaf.2003.31","article-title":"Survival and hospitalization in heart failure patients with or without diabetes treated with \u03b2-blockers","volume":"9","author":"Bobbio","year":"2003","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ahj.2007.01.029","article-title":"The effects of initiation or continuation of statin therapy on cholesterol level and all-cause mortality after the diagnosis of left ventricular systolic dysfunction","volume":"153","author":"Huan Loh","year":"2007","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B60","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ijcard.2016.07.292","article-title":"Prognosis of heart failure with preserved ejection fraction treated with \u03b2-blockers: a propensity matched study in the community","volume":"222","author":"Ruiz","year":"2016","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B61","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ejim.2012.01.011","article-title":"Effect of beta blocker therapy on survival of patients with heart failure and preserved systolic function following hospitalization with acute decompensated heart failure","volume":"23","author":"Nevzorov","year":"2012","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijcard.2009.06.009","article-title":"Mortality and morbidity of newly diagnosed heart failure with preserved systolic function treated with \u03b2-blockers: a propensity-adjusted case-control populational study","volume":"146","author":"Gomez-Soto","year":"2011","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B63","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejheart.2006.07.008","article-title":"Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival","volume":"9","author":"Dobre","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijcard.2014.03.005","article-title":"Beta-blockers in older patients with heart failure and preserved ejection fraction: class, dosage, and outcomes","volume":"173","author":"Patel","year":"2014","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B65","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2016.06.202","article-title":"Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure","volume":"221","author":"Katz","year":"2016","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B66","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00228-012-1400-9","article-title":"Relationship between recommended chronic heart failure treatments and mortality over 8 years in real-world conditions: a pharmacoepidemiological study","volume":"69","author":"Maison","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B67","doi-asserted-by":"crossref","first-page":"659.","DOI":"10.1016\/j.ahj.2010.01.011","article-title":"Predictors for short-term progressive heart failure death in New York Heart Association II patients implanted with a cardioverter defibrillator-the EVADEF study","volume":"159","author":"Marijon","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B68","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0300-8932(09)70379-3","article-title":"Effect of statin treatment on mortality in a large cohort of heart failure patients","volume":"62","author":"Jord\u00e1n","year":"2009","journal-title":"Rev Esp Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B69","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2125.2006.02769.x","article-title":"Effectiveness of beta-blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age?","volume":"63","author":"Dobre","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B70","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11606-007-0197-1","article-title":"The effectiveness of \u03b2-blockers in women with congestive heart failure","volume":"22","author":"Keyhan","year":"2007","journal-title":"J Gen Intern Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B71","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.12.022","article-title":"Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS)","volume":"150","author":"Chan","year":"2005","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B72","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/heart.89.3.299","article-title":"Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience","volume":"89","author":"Maggioni","year":"2003","journal-title":"Heart"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B73","first-page":"331","article-title":"Angiotensin converting enzyme inhibitors and beta-blockers in African Americans with heart failure","volume":"13","author":"McCullough","year":"2003","journal-title":"Ethn Dis"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0002-8703(99)70251-6","article-title":"Insights into the contemporary epidemiology and outpatient management of congestive heart failure","volume":"138","author":"McAlister","year":"1999","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B75","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ahj.2010.08.036","article-title":"Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure","volume":"160","author":"Hamaguchi","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B76","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijcard.2016.11.006","article-title":"Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone","volume":"227","author":"Lam","year":"2017","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B77","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00228-013-1512-x","article-title":"Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study","volume":"69","author":"Frankenstein","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B78","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.amjcard.2013.06.039","article-title":"Effectiveness and safety of spironolactone for systolic heart failure","volume":"112","author":"Lee","year":"2013","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B79","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCHEARTFAILURE.112.000115","article-title":"Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study","volume":"6","author":"Lund","year":"2013","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B80","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1016\/j.ijcard.2013.06.103","article-title":"Spironolactone in mild chronic heart failure: insights from a propensity-matched analysis of the MUSIC study cohort","volume":"168","author":"Pascual-Figal","year":"2013","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B81","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"Hernandez","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cardfail.2006.11.016","article-title":"The effect of spironolactone use on heart failure mortality: a population-based study","volume":"13","author":"Ouzounian","year":"2007","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B83","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1161\/CIRCHEARTFAILURE.111.965160","article-title":"Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure trial","volume":"5","author":"O'Meara","year":"2012","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B84","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijcard.2017.03.014","article-title":"Clinical characteristics and prognosis of patients admitted for heart failure: a 5-year retrospective study of African patients","volume":"238","author":"Bonsu","year":"2017","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B85","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchf.2012.08.001","article-title":"Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction","volume":"1","author":"Patel","year":"2013","journal-title":"JACC Hear Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B86","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjcard.2004.04.059","article-title":"Usefulness of spironolactone in a specialized heart failure clinic","volume":"94","author":"Sligl","year":"2004","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B87","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/CIRCHEARTFAILURE.114.001730","article-title":"Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21,864 patients in the Swedish Heart Failure Registry","volume":"8","author":"Alehagen","year":"2015","journal-title":"Circ Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B88","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijcard.2008.11.042","article-title":"Mortality and morbidity of newly diagnosed heart failure treated with statins: a propensity-adjusted cohort study","volume":"140","author":"Gomez-Soto","year":"2010","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B89","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1751-7133.2009.00057.x","article-title":"Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy","volume":"15","author":"Sumner","year":"2009","journal-title":"Congest Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B90","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.hrthm.2007.12.023","article-title":"Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction","volume":"5","author":"Coleman","year":"2008","journal-title":"Heart Rhythm"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B91","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ahj.2007.02.002","article-title":"Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)","volume":"153","author":"Dickinson","year":"2007","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000095629","article-title":"Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: results of CIBIS II","volume":"108","author":"Krum","year":"2007","journal-title":"Cardiology"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B93","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijcard.2006.07.106","article-title":"Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT","volume":"119","author":"Krum","year":"2007","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B94","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijcard.2006.03.057","article-title":"Statin use and survival in patients with chronic heart failure\u2013results from two observational studies with 5200 patients","volume":"112","author":"Anker","year":"2006","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B95","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jacc.2006.05.053","article-title":"Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy","volume":"48","author":"Goldberger","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B96","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archinte.165.1.62","article-title":"Statin use and survival outcomes in elderly patients with heart failure","volume":"165","author":"Ray","year":"2005","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B97","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.amjcard.2004.01.039","article-title":"Statin therapy is associated with lower mortality among patients with severe heart failure","volume":"93","author":"Mozaffarian","year":"2004","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B98","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cardfail.2008.10.026","article-title":"Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis","volume":"15","author":"Ouzounian","year":"2009","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B99","doi-asserted-by":"crossref","first-page":"e004706.","DOI":"10.1161\/JAHA.116.004706","article-title":"Statin treatment and clinical outcomes of heart failure among Africans: an inverse probability treatment weighted analysis","volume":"6","author":"Bonsu","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00228-015-1980-2","article-title":"Gender differences in statin prescription rates, adequacy of dosing, and association of statin therapy with outcome after heart failure hospitalization: a retrospective analysis in a community setting","volume":"72","author":"Ballo","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B101","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ejim.2009.03.001","article-title":"Discrepancy between results of randomized control studies and retrospective analysis: the case of statin therapy effect on one-year mortality in patients with decompensated heart failure","volume":"20","author":"Nevzorov","year":"2009","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B102","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/07853890903022819","article-title":"Statins in heart failure: retrospective cohort study using routine primary care data","volume":"41","author":"Ryan","year":"2009","journal-title":"Ann Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B103","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/CIRCULATIONAHA.105.591446","article-title":"Statins and mortality among elderly patients hospitalized with heart failure","volume":"113","author":"Foody","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B104","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/jama.296.17.2105","article-title":"Statin therapy and risks for death and hospitalization in chronic heart failure","volume":"296","author":"Go","year":"2006","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B105","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/j.1742-1241.2011.02771.x","article-title":"Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study","volume":"65","author":"Andrey","year":"2011","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B106","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.amjcard.2008.07.014","article-title":"Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy","volume":"102","author":"Dhaliwal","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B107","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2016.11.021","article-title":"The impact of digoxin on mortality in patients with chronic systolic heart failure: a propensity-matched cohort study","volume":"228","author":"Al-Khateeb","year":"2017","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B108","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/CIRCOUTCOMES.111.000079","article-title":"Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure","volume":"6","author":"Freeman","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B109","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1751-7133.2010.00161.x","article-title":"Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT)","volume":"16","author":"Butler","year":"2010","journal-title":"Congest Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cardfail.2004.07.002","article-title":"The effect of gender on outcome in digitalis-treated heart failure patients","volume":"11","author":"Domanski","year":"2005","journal-title":"J Card Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B111","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjmed.2013.08.027","article-title":"Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure","volume":"127","author":"Ahmed","year":"2014","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B112","doi-asserted-by":"crossref","first-page":"e000888.","DOI":"10.1136\/bmjopen-2012-000888","article-title":"Observational cohort study of the safety of digoxin use in women with heart failure","volume":"2","author":"Flory","year":"2012","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B113","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00228-007-0346-9","article-title":"Digoxin and mortality in atrial fibrillation: a prospective cohort study","volume":"63","author":"Hallberg","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B114","doi-asserted-by":"crossref","first-page":"e006035.","DOI":"10.1161\/JAHA.117.006035","article-title":"Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF\u2010TIMI 48 trial","volume":"6","author":"Eisen","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B115","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ijcard.2016.07.111","article-title":"Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: a nationwide propensity score matched study","volume":"221","author":"Madelaire","year":"2016","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B116","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.amjcard.2014.05.013","article-title":"Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients \u226565 years of age with versus without heart failure","volume":"114","author":"Shah","year":"2014","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B117","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/eurheartj\/ehs348","article-title":"Increased mortality among patients taking digoxin\u2013analysis from the AFFIRM study","volume":"34","author":"Whitbeck","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B118","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B119","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B121","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced eft-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B122","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B123","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B124","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine\u2013isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B126","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B127","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B128","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B129","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(05)74355-5","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","author":"Dargie","year":"1999","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B131","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B132","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","article-title":"Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure)","volume":"53","author":"van Veldhuisen","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B133","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJM200105313442202","article-title":"A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure","volume":"344","author":"Beta-Blocker Evaluation of Survival Trial Investigators","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B134","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(97)80008-6","article-title":"A randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease","volume":"349","author":"Australia\/New Zealand Heart Failure Research Collaborative Group","year":"1997","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B135","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS)","volume":"90","author":"CIBIS Investigators and Committees","year":"1994","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B136","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B137","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B138","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B139","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B141","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B142","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B143","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1253\/circj.CJ-12-1062","article-title":"Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure study (PEARL study)","volume":"77","author":"Takano","year":"2013","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B144","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B145","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Digitalis Investigation Group","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B146","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary Digitalis Investigation Group trial","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B147","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0735-1097(01)01442-5","article-title":"Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study","volume":"38","author":"Rich","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B148","first-page":"2095","article-title":"Assumption versus evidence: the case of digoxin in atrial fibrillation and heart failure","volume":"38","author":"Bavendiek","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B149","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1056\/NEJMoa1308789","article-title":"Thrombus aspiration during ST-segment elevation myocardial infarction","volume":"369","author":"Fr\u00f6bert","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11897-017-0325-0","article-title":"Registry-based pragmatic trials in heart failure: current experience and future directions","volume":"14","author":"Lund","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"key\n\t\t\t\t20181001045237_ehy407-B151","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMc1612601","article-title":"Spironolactone metabolites in TOPCAT - new insights into regional variation","volume":"376","author":"de Denus","year":"2017","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/39\/37\/3417\/25857019\/ehy407.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T01:42:19Z","timestamp":1571535739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/39\/37\/3417\/5063542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":151,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2018,8,1]]},"published-print":{"date-parts":[[2018,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehy407","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,10,1]]},"published":{"date-parts":[[2018,8,1]]}}}